cyrilzakka/clinical-trials huggingface dataset:
Intermittent Catheterization Versus Trial Without Catheter

This is a prospective, comparative, multicenter, randomized controlled trial. The aim of this study is to compare the efficacy, safety and quality of life within patients with acute urinary retention managed by the intermittent catheterization compared or indwelling Foley catheter.


Eligibility Criteria:
Inclusion Criteria:

Men with acute urinary retention due to prostatic hyperplasia

Exclusion Criteria:

* Patient's with serious conditions and incapacity
* Previous urethral or prostate surgery.
* Urethral stricture.
* Urethrorrhagia.
* Injuries of urethra and perineum.
* Attempts of bladder catheterization within 15 days before the acute urinary retention episode.
* Urinary tract infection.
* Neurogenic bladder.
* Chronic urinary retention with a bladder volume of more than 1 liter.
* Obstructive uropathy due to the acute urinary retention.
Gut Microbiota Analysis in Patients Undergoing Duodencephalopancreasectomy for Pancreatic Cancer

Pancreatic head cancer represents one of the most frequent malignancies with an incidence of about 13500 new cases each year. The primary objective of the study is to test whether there are bacterial species associated with increased risk of complications in patients with peri-ampullary neoplasia undergoing DCP.

Pancreatic head cancer represents one of the most frequent malignancies with an incidence of about 13500 new cases each year. The only curative strategy for such neoplasm is still surgical resection by duodenocephalopancreasectomy (DCP) surgery. However, this procedure has a postoperative morbidity of about 70% with a severe complication rate of 20%. The most frequent complications are pancreatic fistula, biliary fistula, and infectious complications in general. These complications often account for a high postoperative mortality rate that even in high-volume centers reaches 5%. Although some predictive risk factors are known (comorbidities and the patient's age, the consistency of the pancreatic stump to be anastomized and/or type of pathology treated), there is still no study that has evaluated the influence of the gut microbiota in the determinism of complications. This hypothesis appears suggestive and supported by indirect evidence from the literature. Some preliminary studies performed in the field of colo-rectal surgery have shown that the presence of certain bacterial families such as Lachnospiraceae or Bacteroidaceae are correlated with a significant increase in anastomotic dehiscence. Low microbial diversity also appears to be correlated with increased risk of anastomotic dehiscence. In contrast, the presence of other species such as Prevotella copri or Streptococcus genus seem to correlate with a reduced risk of dehiscence.

The primary objective of the study is: to test whether there are bacterial species associated with increased risk of complications in patients with peri-ampullary neoplasia undergoing DCP.

Other objectives to be verified are:

1. the association between bacterial species and the occurrence of pancreatic fistula in terms of frequency and severity
2. the association between bacterial species and the occurrence of biliary fistula in terms of frequency and severity
3. the association between bacterial species and the occurrence of infectious complications of any kind.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years
* Diagnosis of resectable pancreatic adenocarcinoma with indication for "upfront" surgical treatment
* ASA (American Society of Anesthesiology) score \< 4
* Obtaining informed consent

Exclusion Criteria:

- Pregnant or lactating women
Cera™ ASD Occluder Post-Market Clinical Follow-Up Study

The objective of this post-market study is to:

* collect real-word clinical data and confirm the long-time safety and performance of the Lifetech Cera™ ASD Occluder
* identify previously unknown side-effects

Atrial Septal Defect (ASD) is a type of Congenital Heart Defects (CHD) that have the potential to be closed without open-heart surgery. The treatment of choice for ASD closure has long been surgical closure. An alternative is the use of percutaneous access and transcatheter occluder devices as a treatment option for ASD. With percutaneous closure a thoracotomy is no longer needed and this is associated with a decreased procedural time and shorter hospital stay. The Lifetech Cera™ ASD occluder is a percutaneous, transcatheter closure device for the non-surgical closure of ASD. In order to collect real-word clinical data and confirm the long-time safety and performance of the Lifetech Cera™ ASD Occluder, this post-market clinical follow-up study is planned under the Regulation (EU) 2017/745. The study intends to enroll 139 subjects. The anticipated enrollment period is approximately 1 years and subjects will be followed for 2 years (24 months) post-implantation.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a confirmed diagnosis of secundum Atrial Septal Defect (ASD).
* Patients was implanted with the study device from 01 Jan 2020 to 31 Dec 2023 as per IFU instructions.
* Patients or legally authorized representative are willing to the collection and processing of his/her data or sign the Informed Consent.

Exclusion Criteria:

* Patients who have extensive congenital cardiac anomaly which can only be adequately repaired by cardiac surgery.
* Patients who have sepsis within one month prior to implantation, or any systemic infection that can't be successfully treated prior to device placement.
* Patients known to have a bleeding disorder, untreated ulcer or any other contraindications to aspirin therapy, unless another anti-platelet agent can be administered for 6 months.
* Patients who have demonstrated intra-cardiac thrombi on echocardiography (especially left atrial or left atrial appendage thrombi).
* Patients whose size (i.e., too small to tolerate TEE probe, catheter size, etc.) or condition (active infection, etc.) would cause the patient to be a poor candidate for cardiac catheterization.
* Patients where the margins of the defect are less than 5mm from the coronary sinus, AV valves or right upper lobe pulmonary vein.
* Patients did not conduct any follow up visit after hospital discharge.
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of idelalisib in adults receiving ruxolitinib as therapy for intermediate to high-risk primary myelofibrosis (PMF), post-polycythemia vera, or post-essential thrombocythemia myelofibrosis (post-PV MF or post-ET MF) with progressive or relapsed disease.

This is a dose-escalation study. There will be 4 cohorts (A, B, C, D). Participants will receive an escalating dose or dose frequency of idelalisib based on the safety data of available cohort(s).


Eligibility Criteria:
Key Inclusion Criteria:

* Individuals must have been on a stable dose of ruxolitinib for at least 4 weeks prior to study entry
* Individuals with PMF, post-PV MF, or post-ET MF classified as high risk or intermediate risk as defined by the Dynamic International Prognostic Scoring System (DIPSS) for PMF or DIPSS Plus, if cytogenetics are available
* Individuals with PMF, post-PV MF, or post-ET MF who are receiving ruxolitinib and meet 2013 Revised International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) response criteria with progressive and relapsed disease, with modifications for progressive disease complete remission (CR), partial remission (PR), or clinical improvement (CI)
* European Cooperative Oncology Group (ECOG) performance status of ≤ 2
* Required screening laboratory values as described in the protocol
* Willing and able to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions including mandatory prophylaxis for pneumocystis jiroveci pneumonia (PJP)
* Able to understand and willing to sign the informed consent form

Key Exclusion Criteria:

* Individuals on a stable ruxolitinib dose of 5 mg once daily
* History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
* Ongoing drug-induced liver injury, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver
* Ongoing drug-induced pneumonitis
* Ongoing inflammatory bowel disease
* Ongoing alcohol or drug addiction
* Symptomatic congestive heart failure (New York Heart Association Classification \> Class II), unstable angina, or unstable cardiac arrhythmia requiring medication
* Known hypersensitivity to the study investigational medicinal product (IMP), the metabolites, or formulation excipients
* Unwilling or unable to take oral medication
* Unresolved non-hematologic toxicities from prior therapies that are \> Common terminology Criteria for Adverse Events (CTCAE) Grade 1 (with the exception of alopecia \[Grade 1 or 2 permitted\])
* Pregnant or lactating females
* Cytomegalovirus (CMV): Ongoing infection, treatment, or prophylaxis within the past 28 days

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes

This study is conducted globally. The aim of this study is to describe the proportion of patients with hypoglycaemic episodes and estimate the incidence of various types of hypoglycaemia in the retrospective and prospective periods.


Eligibility Criteria:
Inclusion Criteria:

* Informed consent obtained before any trial-related activities
* Patient with T1DM or T2DM treated with insulin for more than 12 months
* Male or female patient at least 18 years of age at the time of inclusion in the study

Exclusion Criteria:

* Previous participation in this study
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
* Illiterate patients and patients otherwise unable to sign the Informed Consent or complete a written survey
* Non-ambulatory patients
* Simultaneous participation in any other clinical study with an investigational product
Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain

This study is to compare the tolerability of different methods for switching from another medication to duloxetine for the management of diabetic nerve pain. The primary objective is to compare the most gradual method with the most abrupt method, to see if they have different tolerability.


Eligibility Criteria:
Inclusion Criteria:

* You must have been diagnosed with Diabetic Peripheral Neuropathic Pain.
* You must have been taking the same dose of amitriptyline once daily at bedtime for at least four (4) weeks.
* You must have stable glycemic control.
* You must be able to visit the doctor's office once a week for ten (10) weeks.

Exclusion Criteria:

* You are in the acute recovery phase following myocardial infarction.
* You have Major Depressive Disorder, an Anxiety Disorder, or some other psychiatric illnesses that the doctor will ask you about.
* You are allergic to amitriptyline or duloxetine.
* You are currently taking an anticonvulsant, cisapride (Propulsid), or if you have taken an opioid for three or more consecutive days during the 14 days prior to Visit 2.
* You have uncontrolled narrow angle glaucoma.
Genetic Information and Dietary Intake Behaviour

This study's primary objective is to determine if providing individuals with personal genetic information impacts dietary intake behaviour. Specifically, the investigators will be examining whether providing dietary advice based on genes that affect the metabolism of or sensitivity to caffeine, vitamin C, sugar and sodium will impact the intake of these dietary components. The study hypothesis is that providing dietary advice based on genetics will impact dietary behaviour to a greater extent than general dietary recommendations.


Eligibility Criteria:
Inclusion Criteria:

* 20-35 year old participants from the Toronto Nutrigenomics and Health Study

Exclusion Criteria:

* pregnancy or nursing
* vitamin C supplement users
* caffeine intake \< 100 mg/day
* total sugars intake \< 10% energy
* sodium intake \< 1500 mg/day
Leveraging Electronic Health Record Tools to Improve the Evidence-Based Treatment of Children Hospitalized With Bronchiolitis

The goal of this experimental study is to learn whether different types of best practice advisories (BPAs) that direct clinicians to reference clinical guidelines embedded in the electronic health record (EHR) increase the delivery of evidence-based care in children presenting to the hospital with bronchiolitis. The main questions it aims to answer are:

* Do BPAs improve clinicians' delivery of guideline-concordant care in bronchiolitis?
* Do interruptive BPAs improve guideline-concordant care of bronchiolitis more than non-interruptive BPAs?

Researchers will compare the treatment and outcomes of patients whose clinicians did not receive a BPA, to those whose clinicians received a non-interruptive BPA, to those whose clinicians received an interruptive BPA.

Patients will continue to receive standard hospital care for bronchiolitis.

Clinicians will:

* retain access to an EHR-embedded clinical guideline for bronchiolitis care
* be exposed to either no BPA, a non-interruptive BPA, or an interruptive BPA promoting the EHR-embedded clinical guideline (randomized per patient encounter)

Bronchiolitis, a viral respiratory illness affecting infants and toddlers, is the most common reason children less than 2 years old are hospitalized. However, many children admitted with bronchiolitis receive unnecessary treatments that do not hasten recovery and may even cause harm. Despite evidence that the best treatment for bronchiolitis is supportive care (i.e. oxygen and hydration support), clinicians continue to overuse certain therapies, leading to longer hospital stays, higher costs, and increased stress for families.

The investigators will study the effects of BPAs, which are real-time alerts within the EHR. The BPAs in this study promote the use of an evidence-based care guideline for bronchiolitis that is embedded within the EHR. There are multiple BPA designs commonly used in EHRs: 1) interruptive BPAs, which require clinicians to interact with the alert to continue the clinician's workflow; and 2) non-interruptive BPAs, which appear as visual cues but do not require clinicians to alter workflows.

Eligibility Criteria:
Patient Inclusion Criteria:

* Children \<=24 months of age presenting to the emergency room and/or hospitalized (under observation or inpatient status) with bronchiolitis at one of three study sites.

Patient Exclusion Criteria:

* Current encounter is birth-encounter
* Currently hospitalized in an ICU
* Hospitalized with length of stay \>14 days

Clinician Inclusion Criteria:

* Physicians and advanced practice providers entering the patient's chart or orders entry activity for Emergency Department (ED) and inpatient encounters

Clinician Exclusion Criteria:

* Physicians and advanced practice providers who do not enter the patient's chart or orders entry activity
Resistive Diaphragmatic Breathing Exercise With Pursed Lips Breathing Exercise in Sub-acute Stroke Patients

To determine whether resistive diaphragmatic breathing exercise with pursed lips breathing exercise improve pulmonary function in sub-acute ischemic stroke, To determine whether resistive diaphragmatic breathing exercise with pursed lips breathing exercise improve Trunk Control in sub-acute ischemic stroke, To determine whether resistive diaphragmatic breathing exercise with pursed lips breathing exercise improve Functional Capacity in sub-acute ischemic stroke


Eligibility Criteria:
Inclusion Criteria

* Age 40-65 years
* Onset of ischemic stroke in first two week
* First episode of unilateral stroke with hemiparesis during previous 12 months
* Patient with no serious cognitive deficits i-e mini-mental state examination (score \>22) ability to understand, perform and follow simple verbal instructions
* Functional ambulation category (FAC) \>3
* 6 min walk test distance should be \>200 m

Exclusion Criteria:

* Known case of cardiopulmonary disease, BP \> 180/100 mmHg twice in 24 hours
* Known case of neurological disease other than stroke, Known case of orthopedic disease i-e funnel chest, rib fractures or any other orthopedic deformity
* Medication that would influence metabolic or cardiorespiratory responses to exercise Impaired level of consciousness, Evidence of gross cognitive impairment.
Use of Gadolinium in CT Pulmonary Angiography

The study will investigate patients with clinical suspicion for pulmonary embolism (PE) who have a contraindication to iodine based contrast. These patients normally get investigated with studies such as ultrasound and nuclear medicine studies but the fastest and preferred investigation is CT with contrast to look for filling defects in the pulmonary arteries. The investigators will assess whether gadolinium, which is currently used with MRI can be used with CT as an alternative effective contrast in diagnosis or exclusion of PE. A new type of CT scanner, a Dual Energy Scanner will be used to improve the visibility of Gadolinium contrast on CT.

Contrast enhancement with Gadolinium will be evaluated to assess its efficacy for diagnosis and exclusion of pulmonary embolism in a patient who previously would not have been investigated with CTPA due to an underlying allergy to contrast or other contraindication. If this proves beneficial, it will allow such patients to be investigated successfully with CTPA

Eligibility Criteria:
Inclusion Criteria:

* Patients suspected of having a Pulmonary embolus
* Allergy to Iodine based intravenous contrast

Exclusion Criteria:

* Renal impairment
* Less than 20 years of age
* Non-English speaking
* Pregnancy
* Allergy to Gadolinium
Pregnancy Success Rates of Acupuncture for in Vitro Fertilization

This study evaluates the effectiveness of acupuncture on pregnancy success before embryo transfer in IVF treatment in female infertile patients. Half of participants will receive acupuncture sessions before embryo transfer, while the other half will not receive.

Acupuncture is used for many health problem all around the World. WHO reported that acupuncture can have benefit in female infertility treatment. However, there is no enough evidence about effectiveness of acupuncture treatment in the infertility.

Eligibility Criteria:
Inclusion Criteria:

* To have unexplained infertility
* To go in vitro fertilization treatment
* To give permission by informed consent form

Exclusion Criteria:

* Below age of 18 and above age of 45
* To have secondary infertility
* To reject completing informed consent form
Kendall Exercises on Posture-Related Cervical Spondylosis

This study evaluates the effectiveness of Kendall exercises in correcting postural deviations, such as forward head posture, associated with cervical spondylosis. By targeting muscle imbalances and improving alignment through stretching and strengthening protocols, the research aims to reduce symptoms, enhance cervical spine function, and promote postural health. Participants will undergo a four-week exercise intervention with pre- and post-assessments to determine the outcomes.

This study investigates the impact of Kendall exercises on posture-related cervical spondylosis, a degenerative condition often linked to postural deviations like forward head posture (FHP). Prolonged poor posture, frequently exacerbated by activities such as excessive smartphone or computer use, leads to muscle imbalances, increased mechanical stress on the cervical spine, and degenerative changes in intervertebral discs and joints.

Kendall exercises are targeted therapeutic interventions designed to address muscle imbalances by strengthening weak muscles (e.g., deep cervical flexors) and stretching tight muscles (e.g., upper trapezius, pectoralis muscles). These exercises aim to restore proper alignment, reduce mechanical strain, and improve overall posture and cervical function.

Participants with posture-related cervical spondylosis will engage in a four-week exercise protocol involving specific Kendall exercises for cervical extensors, flexors, shoulder retraction, and chest muscles. Outcomes will be assessed using craniovertebral angle measurements, photographic analysis, and subjective pain/function scales. The study seeks to establish Kendall exercises as a non-invasive, effective intervention for managing cervical spondylosis by correcting postural deviations and mitigating associated symptoms

Eligibility Criteria:
Inclusion Criteria:

* • Already diagnosed patients of cervical radiculopathy confirmed by clinical examination and imaging

  * A patient with a Forward Head Posture (FHP) (CVA angle less the 48-50 degrees is defined as Forward head posture
  * Positive Spurling test
  * Numbness of the arm, fingers, or shoulder
  * Cervical Postural assessment showing asymmetry (radiographic Analysis, and Posture Observation)
  * Chronic symptoms ≥ 1 year
  * Pain and Stiffness which limited range of motion in the cervical spine (Flexion less than 60°) (Extension less than 73°) (Lateral Flexion less than 13°-23° Rotation less than 80°)
  * Pain: moderate to severe level (≥5 on NPRS)

Exclusion Criteria:

* • History of Recent trauma to the cervical spine

  * Any psychological condition
  * Any specific cause of cervical radiculopathy (e.g., metabolic diseases, rheumatoid arthritis, osteoporosis)
  * Central or peripheral neurological signs
  * History of spinal surgery.
Electrical Dry Needling Versus Iontophoresis in Treating Chronic Unilateral Knee Osteoarthritis

The goal of this clinical trial is to compare the effects of electrical dry needling versus glucosamine sulfate iontophoresis on pain intensity level, functional ability, and knee range of motion in chronic unilateral knee osteoarthritis patients.

Knee Osteoarthritis (OA) is a chronic disease affecting 240 million people worldwide, with a higher prevalence in older adults. The disease leads to knee deformity, laxity, and ligament instability. Dry needling, a new treatment modality, uses needle electrodes to deliver an electric current to the pain-generating trigger point, improving the physiological effects and analgesic and anesthetic effects. Iontophoresis, a safer method of drug therapy, has shown to be more effective in pain reduction in knee osteoarthritic patients. The study aims to investigate the effect of electrical dry needling versus glucosamine sulfate iontophoresis on pain intensity level, knee function, and range of motion (ROM) in chronic knee OA patients. This approach aims to maximize drug bioavailability, optimize therapeutic efficacy, and minimize side effects.

Eligibility Criteria:
Inclusion Criteria:

1. The patient will be selected from the outpatient clinic of physical therapy at Horus University, New Damietta, Egypt, diagnosed with a Kellgren/Lawrence grade 2,3 radiological severity of knee osteoarthritis (OA). and referred by an orthopedist.
2. Age will range from 40 to 60 years.
3. Body mass index will range from 25 to 29.9 kg/m2.
4. Duration of knee pain not less than 3 months prior to study .

Exclusion Criteria:

1. Patients with history of cardiac disorder with pacemaker.
2. Knee surgery.
3. Diabetes and nutritional disorder.
4. Neuromuscular and other musculoskeletal diseases.
5. Any red flags to dry needling, or conventional therapy.
6. Had received physical therapy, acupuncture, massage therapy, chiropractic, or intra-articular injections for the painful knee in the last 3 months.
7. Presented with positive neurological signs.